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Abstract 
Rift Valley fever virus is an emerging zoonotic pathogen that infects domestic ruminants and 
causes fatal hepatic necrosis and “abortion storms” that result in loss of up to 90-100% of 
pregnancies in animals. Human infection occurs among individuals in contact with affected 
animals and typically manifests as a febrile illness that can advance to hemorrhagic fever or 
neurological disease. In patients that develop encephalitis, there is a 50% chance of death while 
survivors experience long-term complications. Human cases of vertical transmission during 
pregnancy resulted in fetal viremia, abnormalities, and death; however, the rates of congenital 
RVFV are misunderstood and understudied. Rodent encephalitic and congenital models of RVF 
have recently been developed and are crucial for elucidating the mechanism of infection separating 
febrile illness from severe outcomes effecting the central nervous and reproductive systems. 
Whole, homogenized tissues from these models have been analyzed for viral titers, infiltrating 
immune cells, and resulting pathologies; however, specific infection events occurring within 
precise tissue structures required immunofluorescence and chromogen staining for microscopic 
image analysis and scoring. Thin sections of tissues from both models were stained for viral and 
cellular markers and imaged in order to determine specific disease events observed in our lab’s 
previous studies, Albe et al. (2019) and McMillen et al. (2018). Immunofluorescence micrographs 
 v 
supported the presence of vRNA and inflammatory leukocyte infiltration in the olfactory bulbs 
and cortexes as early as 1 day post-infection (dpi), and massive neuronal infection and necrosis 
beginning by 3 dpi. End-stage neurological disease, beginning at 5 dpi, was represented by a 
massive blood brain barrier breakdown event and influx of inflammatory cells. Histological 
analysis of pregnant RVFV-infected rat tissues showed the highest amount of vRNA in the 
placental tissues rather than the liver, and moderate levels of virus in the uterus and ovaries. Within 
the placenta, RVFV targeted the maternal decidual layer and fetal basal and labyrinth zones. Viral 
signal was also detected in the placentas of dams that survived infection. Visual 
immunohistochemistry data, as developed and presented here, can help highlight structural and 
cellular targets of RVFV that should be focused on for therapeutic efforts. RVFV is in the Federal 
Select Agent program for pathogens that have the potential to post a severe threat to public, animal, 
or plant health, on the World Health Organization’s list of Blueprint priority diseases requiring an 
urgent need for accelerated research and development, and a category A high-priority pathogen of 
the National Institute of Allergy and Infectious Diseases, which are biological agents that post the 
highest risk to national security; therefore research into therapeutics for RVF is of major public 
health significance.  
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1.0 Introduction 
Rift Valley fever virus (RVFV) is a zoonotic pathogen of the Phenuiviridae family 
(previously Bunyaviridae) and Phlebovirus genus. This family consists of enveloped, negative-
sense, single-stranded RNA viruses containing a tri-segmented genome; the individual segments 
are denoted as small (S), medium (M), and large (L). The genome of RVFV is highly conserved 
(1), approximately 11.9 kilobases long, and encodes six proteins. The S segment is ambisense and 
contains a non-structural protein (NSs) and the nucleoprotein (NP). The M segment contains the 
Gc and Gn glycoproteins and another non-structural protein (NSm). The L segment contains the 
RNA-dependent RNA polymerase. NSs is the major virulence factor of RVFV and acts as an 
antiviral immune response antagonist (2).  
RVFV is endemic to the African continent and commonly infects ruminant livestock such 
as sheep, cattle, goat, and camels via mosquito bite of the Aedes and Culex species (3-6). Infected 
animals may develop fatal hepatic necrosis or experience “abortion storm” events which may cause 
up to 100% neonatal mortality within a herd (7). Adult animals experience a 10-20% mortality 
rate. Humans may contract Rift Valley fever (RVF) via mosquito bite or respiratory exposure to 
aerosolized virus from infected animal tissues. Individuals will typically experience a self-limiting 
febrile illness that can progress to hepatitis, ocular disease, and encephalitis in 1-2% of cases. 
Human mortality rate likely suffers from underreporting but is currently estimated to be at around 
1% of cases (1). Aerosol exposure increases the likelihood of complications such as encephalitis 
which constitutes over a 50% mortality rate (8); farmers, veterinarians, and butchers are high risk 
populations for this outcome.  
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RVFV is on the list of Federal Select Agents and Toxins due to its potential to “pose a 
severe threat to public, animal or plant health or to animal or plant products” (9). The World Health 
Organization (WHO) also considers RVF to be a public health concern and has it on the Blueprint 
list of Priority diseases for accelerated therapeutic research and development efforts. The current 
vaccines for livestock are either ineffective or teratogenic and, currently, there are no therapeutics 
to treat severe disease among humans. While outbreaks have only occurred on the African 
continent, Arabian Peninsula, and Madagascar, the mosquito species that are competent to transmit 
RVFV also inhabit North America and Europe. Other mosquito-borne viruses, Chikungunya virus 
(CHIKV) and West Nile virus (WNV), can serve as examples of imported pathogens that were 
able to successfully find reservoirs in the Americas (10). The potential for RVFV to spread to 
naïve populations is of major concern for human and animal health due to the ability to cause 
severe disease and economic burden.  
1.1 Rift Valley Fever Virus 
1.1.1  Epidemiology and Transmission 
The first recorded animal outbreak of RVFV occurred in the Rift Valley of Kenya in 1931. 
The British Division of Veterinary Research investigated an abrupt and severe illness among lambs 
which resulted in death 24-hours after initial symptom onset (11). Severity of disease was age-
dependent with mortality rates near 95% among 3-7-day old lambs. Abortion storms occurred 
among asymptomatic pregnant ewes, while non-pregnant adult sheep experienced lethargy, 
vomiting, and diarrhea (12). Postmortem examination of the infected animals showed extensive 
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liver necrosis (12). It is likely that RVF epizootic outbreaks occurred before 1931 since high-
mortality miscarriage events among livestock were noted previously. RVF epidemics have since 
spanned many regions of Africa such as Kenya (12-14), Egypt (14, 15), Sudan (16), Tanzania (14, 
17), Mauritania (18, 19), and the Middle East (8). In 2000, the first recorded outbreaks outside of 
Africa occurred in the Saudi Peninsula, Yemen (2),, and Madagascar (20). Recent outbreaks in 
Gambia and South Sudan in 2018 highlight the continued prevalence of this disease in Africa and 
the Middle East (14).   
Scientists and veterinarians involved in the 1931 Rift Valley outbreak investigation were 
the first humans to test seropositive for RVF. Samples from farmers of infected herds were 
retroactively tested and also found to have RVFV-specific neutralizing antibodies (12). Disease 
was reproduced in another human subject via needle injection with blood from an infected lamb. 
The patient developed a “dengue-like” illness including “fever, headache, abdominal pains, joint 
and muscle pains, photophobia, retro-orbital pain, vomiting, nosebleeds, and sweating.” (12).  
Human epidemics highlight the increased incidence of RVF in populations that raise and 
cohabitate with livestock. In 1977, Egypt experienced the deadliest outbreak to date with 200,000 
infections and 600 deaths (15); strain ZH501 was collected and purified from this outbreak and is 
currently used as one of the most pathogenic laboratory strains. A more recent outbreak in 2007 
that occurred in Sudan had 747 confirmed cases of RVF and 230 deaths; although the total number 
of cases is thought to be closer to 75,000 and underreported due to lack of medical infrastructure 
and the similarity of RVF symptoms to other diseases (16).  
RVF outbreaks occur during times of heavy rainfall and flooding which promote breeding 
of mosquito species in the Culicidae family. The major mechanism of persistence during inter-
epidemic periods is transovarial transmission from mosquitos to offspring, bloodmeal infection of 
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livestock or wild ruminants, and infected livestock infecting naïve mosquitos (21). Field 
seroprevalence investigations show that RVFV can infect a wide range of wild ruminants such as 
buffalo (22), waterbuck (22), impala (22, 23), and kudu (22) and non-ruminants such as warthogs 
and domesticated pigs (24).  There are similar American species such as pronghorn, elk, and deer 
that could act as a reservoir in the event of RVFV spreading to the United States (US) (21). White-
tailed deer are widely distributed across the US with territories overlapping with humans. They 
are a common source of bloodmeals for mosquitoes and are reservoirs for other bunyaviruses such 
as La Crosse virus (LACV), Jamestown Canyon virus (JCV), and Cache Valley virus (25). Five-
month-old male white-tailed deer were subcutaneously injected with wildtype (WT) RVFV 
(Kenya 2006 strain) and developed high viral titers at 2 days post-infection (dpi) (26). Two of the 
five deer developed bloody diarrhea and died by 3 dpi. Severe hepatic necrosis and enteritis were 
found in the two deer with diarrhea during necropsy. The uninfected control deer developed RVF 
symptoms shortly after exposure to bloody diarrhea which suggests horizontal transmission from 
infected feces. Cell lines of other US species such as pigs, dogs, cats, coyotes, and frogs (21) were 
permissive to RVFV infection. This suggests that RVFV introduction into the US could have 
critical effects on wildlife and domesticated animals.  
The lack of vaccines and therapeutics towards RVFV infection and its ability to cause 
severe disease via inhalation requires it to be studied under biosafety level 3 (BSL-3) containment 
requirements. Researchers must don positive air pressure respirators and work in negative pressure 
laboratory spaces. At least 25 accidental lab-acquired infections occurred through 1949 (27, 28) 
with a total of 47 to date. These incidents were mostly caused by aerosol exposure. 
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1.1.2  Viral Replication  
Glycoproteins, Gn and Gc, aid in host cell attachment, entry, replication and release of 
RVFV by recruiting the viral RNA-dependent RNA polymerase to the golgi apparatus and packing 
of viral NP (29). RVFV enters host cells using caveolin-1-mediated endocytosis with DC-SIGN 
(found on dendritic cells and macrophages) and heparan sulfate (expressed by most cell types) as 
mediating cell surface markers (29-31). Viral replication occurs in the cytoplasm with one cycle 
lasting about 10-12 hours (32). The nonstructural proteins of RVFV can hijack the immune system. 
NSm delays virus-induced apoptosis which allows for infected cells to evade death and spread 
virus (33, 34). NSs inhibits interferon (IFN) production by blocking transcription of the interferon-
beta (IFN-B) promoter and transcription factor II H (TFIIH) (34); this mechanism prevents 
induction of antiviral genes in infected cells (32, 35). NSs also inhibits host RNA polymerase II 
which prevents successful synthesis of IFN mRNAs (36). Gn, Gc, and NP are the common 
antigenic proteins and are targets of therapeutics currently in development but have yet to gain 
U.S. Food and Drug Administration (FDA) approval.  
1.1.3  Pathogenesis and Disease in Humans 
RVFV has an incubation period of about 4-6 days. Initial flu-like symptoms start abruptly, 
namely: chills, malaise, dizziness, weakness, headache, and nausea. Fever resulting in an elevated 
body temperature between 38.8 °C and 39.5 °C is accompanied by decreased blood pressure, body 
pains, rigor, shivering, red or sore eyes, constipation, insomnia, and photophobia (37). Epistaxis, 
abdominal pain, vomiting, and diarrhea can occasionally develop. Fevers typically dissipate within 
three days and body temperature will return to normal. RVF may result in a biphasic fever 1-3 
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days after initial fever recovery that can last up to ten days (38). About 1% of RVF cases result in 
mortality; death typically occurs 3-6 days after severe symptom onset (1). These patients typically 
have elevated liver enzymes, aspartate transaminase (AST) and alanine transaminase (ALT), and 
decreased platelets. Liver hemorrhage is the most common cause of death, though, there are few 
cases where renal failure and thrombosis were present in the absence of liver pathology.  
Neurological disease develops in about 1-2% of severe RVF cases and is characterized by 
symptoms such as ataxic gate, retinal hemorrhage, meningeal irritation, confusion, coma, hyper-
salivation, teeth-grinding, and visual hallucinations (37). Pathological observation into tissue 
samples from patients with neurological disease show brain lesions with neuronal necrosis, 
immune cell infiltration and perivascular cuffing (37). Ocular disease may develop alongside 
neurological symptoms and will resolve itself in about 50% of cases, however, if RVFV causes 
lesions to develop in the macula or retina of the eye patients may experience permanent vision loss 
(8, 39, 40).  
Human vertical transmission of RVFV is understudied and likely underreported, however, 
the high rates of fetal abortions among livestock make this source of infection one of concern. 
There are two case studies showing evidence of congenital RVF in humans. A pregnant Sudanese 
woman with RVF symptoms and RVFV-specific IgM delivered a child with RVFV-specific IgM 
exhibiting skin rash, enlarged spleen and liver, and jaundice (41). Another pregnant woman with 
an ongoing RVF infection gave birth to an infant who died within a week from the disease (42). A 
cross-sectional study of 130 pregnant Sudanese women showed higher rates of second and third-
trimester miscarriages in individuals with confirmed RVF infection (43). 
McMillen et al. (2018) infected human placental explants with RVFV to evaluate tissue 
permissivity. RVFV efficiently replicated within the chorionic villi and outer syncytial layers; 
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these tissues exhibited a 2-3 log increase in virus production between 12-36 hours post-infection 
(hpi) (44). RVFV targeted the villus structure and syncytiotrophoblast cells which can resist many 
other viruses, such as Zika virus (ZIKV) (45). Pregnant rats, often used in human placental 
development and toxicology studies, were also found to transmit RVFV to their offspring in utero 
(44) similar to what is observed in livestock and humans.  
1.1.4  Prevention and Treatment  
The most promising preventative method for RVF infection and disease in livestock is 
prophylactic vaccination. The first live-attenuated vaccine for livestock was developed in the 
1960’s and was found to be teratogenic in pregnant ruminants. There are no vaccines or antiviral 
treatment options available for RVFV infection in humans (46, 47); supportive care is the only 
option to treat severe disease outcomes such as hemorrhagic fever or neurological disease (14). 
Due to the ability of RVF infection to result in hepatic, hemorrhagic, neurological, or ocular 
disease, there is a critical need for therapeutics that target each unique outcome.  
Smithburn, the first vaccine strain, was developed by serial passaging virulent RVFV in a 
mouse brain (48). Vaccination with this strain caused abortions and had teratogenic effects in 
livestock, therefore it was only used for non-pregnant animals during severe outbreaks. A 
formalin-inactivated version was produced but had decreased efficacy and required boosters. A 
cause for concern with bunyaviruses is their ability to reassort with others within the order (49); 
reassortment with virulent strains is a risk for all attenuated vaccines (50).  
The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) 
developed an attenuated vaccine strain of RVFV, MP-12, in response to the devastating 1977 
outbreak in Egypt. Virulent ZH548 was passaged in the presence of 5-fluorouracil to induce 
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mutagenesis in all three RNA segments (51, 52). MP-12 is licensed and approved for veterinary 
use in the United States and is safe and efficacious in non-pregnant animals (53). A vaccine trial 
in sheep showed that MP-12 also induced abortions and teratogenesis during early pregnancy. 
However, MP-12 is currently in a phase II clinical trial for human prophylactic use (54); studies 
evaluating vaccine safety for pregnant individuals will need to be carried out.  
Another vaccine strain of RVFV, Clone 13, contains a deletion in the NSs coding region 
(55); due to this large deletion, it is highly unlikely that this strain can revert to WT without 
reassortment with a pathogenic strain.  Immunization with this strain was found to stimulate strong 
antibody responses and did not cause abortions or teratogenesis. This vaccine is not FDA approved 
but is utilized for livestock in places experiencing outbreaks (56). 
Palliative care is the only means of treatment for RVF (38). Nucleoside analogs, such as 
ribavirin and favipiravir, have been investigated for antiviral use. Ribavarin was approved for 
treatment of RNA virus diseases such as Bolivian hemorrhagic fever (BHF), Lassa fever, and 
Argentine hemorrhagic fever (AHF) (57, 58). Ribavarin was also used in a mouse model of Punta 
Toro virus (phlebovirus) infection. It significantly impaired viral replication and resulted in 100% 
survival in animals given subcutaneous (SUBQ) (59) or intraperitoneal (IP) (60, 61) challenge with 
daily SUBQ administration. However, aerosol-challenged mice were not protected (62). Side 
effects such as inflammation and hemolytic anemia can develop from use of ribavirin (63). 
Favipiravir is a polymerase inhibitor that is currently approved for use in influenza-infected 
patients in Japan. It had also been found to be efficacious as a broad-spectrum antiviral against 
various RNA viruses in the filo-, aerna-, paramyxo-, and bunyavirus orders (59, 64-68). In vitro 
studies show promising antiviral effects against bunyaviruses, including RVFV, by protecting 
against acute hepatic infection (64). In a RVFV hamster model, favipiravir given twice orally for 
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10 days protected 80% of the infected animals (59). Favipiravir cannot easily cross the blood brain 
barrier (BBB) and would not be successful as an antiviral for neurological RVF (59, 69).  
Virus-like particles (VLP) against RVFV may bridge the gap between the development of 
efficacious immunogenic therapies without pathogenic viral reversion or health side effects. VLP-
based vaccines do not contain viral genetic material and can be made using baculoviruses (rBV) 
expressing RVFV Gn, Gc, and NP proteins (70). RVFV VLPs induced high virus-neutralizing 
antibody titers in mice given three immunizations and eleven out of twelve mice survived infection 
(71). RVF virus replicon particle (VRPRVF) vaccines have also been efficacious in mouse models 
at only a single dose (72). This agent can actively synthesize RVFV viral RNA (vRNA) and 
proteins but lacks glycoprotein genes, because of this, there is a low chance of reverting to 
virulence (72). It was found safe for intracranial inoculation of suckling mice and completely 
protected against 100,000 times the median lethal dose (LD50). The RVFV VLP and VRPRVF 
vaccines induced a systemic antiviral and adaptive immune response without the risk of pathogenic 
reversion and should be further explored as treatments.  
1.1.5  Public Health Significance  
RVFV is listed as a category A high-priority pathogen by the National Institute of Allergy 
and Infectious Diseases (NIAID) and a select agent by the United States Department of Health and 
Human Services (DHHS) and Department of Agriculture (USDA) due to its potential for 
introduction into the country, intentionally or accidentally, and its ability to cause severe disease 
in naïve populations for which there are no approved therapeutics. The Centers for Disease Control 
(CDC), NIAID, and the USDA deem RVFV a select agent because of its capability to be used as 
a bioterrorism agent if aerosolized. Research by the United States and Russia during the Cold War 
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found that aerosolized RVFV was stable (with a half-life of 77 minutes at room temperature and 
30% relative humidity) and could successfully spread via inhalation (73). The WHO modeled  the 
ability of RVFV to spread in the event of a bioterrorism attack and determined that if an aircraft 
released 50 kilograms of virus over a population of 500,000 individuals that an estimated 35,000 
people would be incapacitated and, of those, 400 would die (74). 
International travel broadens the risk for RVFV spread to naïve countries; over 97% of 
individuals traveling to the United States from RVFV-endemic countries typically arrive at airports 
in densely populated cities such as New York City, Washington DC, Atlanta, Baltimore, Newark, 
and Houston (75). Europe, North America, and South America have the Aedes and Culex mosquito 
species that can serve as vectors for disease as well as domestic and wild ruminants that can act as 
a reservoir (21, 26). Climate change has also increased the range of mosquito species already 
harboring RVFV. It has also been shown that a single infected mosquito can be sufficient for viral 
invasion to a naïve country (76). In the event of its spread to the United States, RVFV could have 
devastating consequences for humans and livestock. 
The Zika virus outbreak in the Americas in 2015-2016 raised concerns over the congenital 
and neurological side effects of infection in pregnant women and their offspring. Of 28,000 
confirmed Zika cases, about 1,000 (4%) were pregnant women (40). The two human case studies 
of vertical transmission of RVFV mimicked the phenomena seen in livestock and prompted the 
development of a rodent model of congenital infection in McMillen et al. (2018). Pregnant rat 
dams that survived infection gave birth to offspring with severe congenital abnormalities which 
emphasizes the long-term consequences of RVFV infection even in subclinical cases. These 
findings highlight the need to develop therapeutics for sensitive populations including pregnant 
women and developing fetuses. 
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1.2 Animal Models 
1.2.1  Mice 
Mice are very susceptible to RVFV infection and require an attenuated strain lacking the 
major virulence factor, NSs, in order to survive infection long enough for observation. Mice 
infected with wildtype RVFV strains (ZH501 and ZH548) will show decreased activity in 2-3 days 
and typically die within 24 hour of symptom onset. Death consistently occurs within 3-5 days due 
to fatal hepatitis regardless of dose or exposure type (77). Mice given an attenuated RVFV strain 
with a deletion in the NSs gene (del NSs) intranasally will develop lethal neurological disease and 
die within 7-9 days. Del NSs footpad injection results in subclinical disease characterized by a 
rapid and robust antibody response and T cell involvement (77). Mice lacking functional IFN-
alpha/beta systems (IFNAR-/-) also develop severe disease when exposed to attenuated RVFV 
strains such as MP-12 due to the inability to mount any IFN-based antiviral responses (78). These 
strains are useful for studying attenuated vaccinations containing DNA plasmid vector encoded 
RVFV segments and their ability to prevent disease despite the mice not having a proper antiviral 
response (79).  
RVF pathology in the mouse model mimics what is observed in lambs, namely, an acute 
hepatic disease with the potential to lead to encephalitis. Hemorrhagic fever and ocular disease do 
not occur in any mouse strains (80). Histological analysis shows eosinophilic inclusion bodies in 
hepatocytes and lymphocyte apoptosis during hepatic disease and neuronal necrosis, 
microvascular hemorrhaging, and perivascular cuffing in neurological disease (80).  
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Although mouse models are invaluable for exploring the differences between immune 
responses between lethal and subclinical RVF in mice, the inability to use pathogenic RVFV is a 
major limitation. 
1.2.2  Rats  
RVF disease outcome in rats is dependent on the strain (56), dose, and exposure route (81). 
Wistar-Furth rats succumb to hepatic disease and viremia within a few days of SUBQ infection 
with pathogenic RVFV (56). August Copenhagan Irish (ACI) rats are only moderately susceptible 
to subcutaneous infection and about 50% succumb to neurological disease similar to what is 
observed in humans (56). Lewis rats do not develop clinical disease after SUBQ infection but 
become viremic and by the end of infection no virus is found in the brain, other tissues, or blood 
(56). The Hartman lab has developed both a reproducible immunocompetent rat model of 
encephalitic disease in Lewis rats and a congenital model in pregnant Sprague-Dawley rats (44, 
82). 
When infected with 103 plaque-forming units (pfu) of ZH501 via inhalation of small 
particle aerosols, Lewis rats will develop encephalitic disease within 5-7 days post-infection (dpi) 
and succumb by 6-7 dpi. Clinical symptoms manifest as fever, weight loss, ruffled fur, hunched 
posture, and porphyrin staining of the eyes, nose, and mouth. Neurological symptoms manifest as 
cage circling, horizontal rolling, head tilting, head and neck tremors, and erratic behavior such as 
jumping. Prior to the clinical window of disease there are alterations in leukocytes and 
inflammatory cytokines (82). Moderate levels of virus (104-106 pfu/g) were detected in the lung 
from 1-5 dpi (peaking at 3 dpi) which decreased to undetectable levels by 7 dpi; despite viral 
infiltration of the lung, there were no noticeable pathological changes. Liver and spleen are primary 
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targets of viral replication in livestock and most rodent models of RVFV, however, in the Lewis 
rat model, liver and spleen displayed low levels (102-103 pfu/g) of infectious virus at 3-4 dpi and 
had no noticeable pathological changes or elevated liver enzymes. The brain had detectable viral 
RNA at 1 dpi and infectious virus by 5 dpi (107-109 pfu/g) which persisted for the duration of the 
study (7 days). Lymphocytic meningitis, vasculitis of lymphocytes, neutrophils, and cortical 
neurons with apoptotic morphology were evident in the rats by 6-7 dpi. Infectious virus was also 
found in the eyes. Immunohistochemistry (IHC) staining showed an association between apoptotic 
cells and viral antigen. Cytokine dysregulation is also a feature of this model showing elevated 
levels of MCP-1, M-CSF, Gro/KC, RANTES, and IL-1β which peak at 4 dpi, suggesting 
monocyte, macrophage, and neutrophil recruitment to the CNS. Elevated levels of MCP-1, 
RANTES, and Gro/KC have also been seen in other viral encephalitic diseases such as tick borne 
encephalitic (TBE), Semlike forest virus (SFV) and WNV (83, 84).  
Walters et al. (2019) found elevated levels of matrix metalloproteinase 9 (MMP-9), an 
enzyme that modifies BBB integrity by degrading tight junctions and extracellular matrix of 
vascular endothelium, in RVFV-infected Lewis rats given aerosol challenge. MMP-9 elevation is 
concurrent with increasing viral RNA levels towards end stage disease. Vascular imaging of 
infected rat brains observed a minor blood brain barrier (BBB) leakage event, occurring on 1 dpi, 
followed by viral RNA entry into the brain. A massive leakage event occurred 4-5 dpi right before 
clinical manifestation of symptoms (85). MMP-9 is also involved in WNV entry into the brain 
after a BBB opening event in mice (86). Vascular breakdown is also a component of infection by 
LACV (87). 
Albe et al. (2019) observed vascular leakage, viral entry, and immune cell infiltration into 
the brain of rats given 103 pfu of pathogenic RVFV via aerosol. Lewis rat serial sacrifice 
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experiments compared aerosol and SUBQ exposure disease manifestations. An LD50 of 10
2 pfu 
was observed for aerosol exposure with 100% mortality over the 7-day infection period whereas 
the LD50 for SUBQ exposure was greater than 10
5 pfu and only resulted in about 20% mortality. 
A steady rise in viral RNA in the central nervous system (CNS) tissues began at 1 dpi and peaked 
to 107 pfu/g in the aerosol model; spleen and liver reached similar titers by end stage infection. In 
the SUBQ model, the CNS tissues only reached 102 pfu/g (as early as 1 dpi) but reached 105 pfu/g 
in the liver by 4 dpi. Total white blood cells (WBC) and platelets followed similar patterns until 
the 5-7 dpi clinical window where WBCs increased to the end of infection in aerosol exposure and 
slowly declined in SUBQ exposure. The aerosol model was characterized by a massive infiltration 
of neutrophils and leukocytes (CD45+ cells) during 5-7 dpi. Cells being labeled with CD45 are 
characterized as: CD45high being infiltrating monocytes, macrophages, and activated microglia and 
CD45med being quiescent microglia (88).  
A decrease in lymphocytes at 3 dpi marked the first change in blood composition followed 
by granulocytosis and thrombocytopenia for the duration of infection. Neutrophils are also the first 
immune cells to enter the brain of Lewis rats during the clinical window of encephalitic disease 
(82, 88). These symptoms are similar to neurological RVF in humans (8, 37, 89).  
An understudied mechanism of infection for RVFV is its ability to enter the brain through 
the olfactory epithelium after aerosol exposure. The connection between the olfactory nerve and 
the CNS is short and channels formed between individual olfactory neurons can fit particles up to 
100nm (90), thus bunyaviruses, which are 90 to 100 nm in diameter (90), can pass. Rats exposed 
to aerosolized RVFV exhibit neutrophil and monocyte influx into the brain at the beginning of the 
clinical window, although virus is seen as early as 1 dpi (88). Since RVFV reaches the brain by 1 
 15 
dpi in both the aerosol and SUBQ route but only causes mortality in the aerosol model, 
investigation into viral activity in the olfactory epithelium is crucial.  
McMillen et al. 2018 developed the first reproducible rodent model of congenital RVFV 
in Sprague-Dawley (SD) rats. Pregnant rats that were subcutaneously infected with ZH501 
exhibited vertical transmission and intrauterine fetal death similar to what is seen in livestock (81). 
Vertical transmission occurred in both rats that succumbed to RVF and rats that survived. Sublethal 
rats gave birth to still-born pups with gross pathological changes such as fluid accumulation (fetal 
hydrops), gray discoloration, and stunted development (44). Viral titers, in this model, were higher 
in the placenta than the liver which challenges RVFV hepatotropic nature after SUBQ exposure 
(44). Rat and human placentas have morphological differences; however, they are similar enough 
that rats are commonly used to study placental development and vaccine teratogenicity during 
pregnancy (91). Both human and rat placentas are hemochorial and have maternal blood in direct 
contact with the chorion membrane that surrounds the embryo. There is also deep, intrauterine 
trophoblast cell invasion which facilitates blood exchange between maternal and fetal tissues; this 
gives pathogens a direct infection pathway to the fetus (92).  This model of disease is poorly 
understudied. Utilizing a reproducible animal of congenital RVF can help elucidate the cellular 
targets of the virus and gestational stages in which protective therapeutics should be aimed. 
Studying the effects of RVFV on reproductive and fetal tissues is also crucial for mitigating 
negative effects in current live-attenuated vaccines.  
1.2.3  Non-Human Primates 
Rhesus macaques are the most commonly used non-human primate (NHP) model in RVF 
studies and develop a nonlethal fever after aerosol exposure. Various infection routes 
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(subcutaneous, intravenous, and aerosol) have resulted in viremia, non-lethal fever and, rarely, 
lethal hemorrhagic disease. Low viral replication was noted from serum antibody titers (93). The 
Hartman lab has published RVFV infection data in three other NHP species: cynomolgus macaque, 
African green monkeys (AGM), and marmosets in order to categorize and develop an encephalitic 
model more phylogenetically similar to that of humans. Cynomolgus macaques developed fever 
similar to rhesus macaques but did not develop neurological disease (93). Marmosets succumbed 
to severe neurological disease from intranasal (93, 94) and low-dose aerosol exposure; encephalitis 
was observed at high-dose aerosol exposure (93). Subcutaneous infection of marmosets resulted 
in hepatitis and hemorrhagic fever.  AGMs experienced similar neurological disease when infected 
via aerosol with 5 out of 6 succumbing to encephalitis. Subcutaneous exposure, however, produced 
no symptoms or deaths. Enzyme-linked immunosorbent assay (ELISA), complete blood count 
(CBC), and blood chemistry analyses showed high amounts of RVFV IgG in the brain tissues, 
decreased platelet counts, and granulocytosis similar to that seen in the Lewis rat encephalitic 
model (93). This preliminary study on marmosets and AGMs has laid a foundation for the use of 
these models in exploring neurological RVF.  
1.2.4  Other models  
RVFV infection in other rodents results in unique outcomes. Syrian hamsters are very 
susceptible and die from liver disease 2-3 days post-infection, similarly to mice. Neutralizing 
antibody treatment can prevent liver necrosis, but fatal encephalitis usually develops by 11 dpi 
(95). Gerbils develop encephalitis with severity being age dependent. 10-week old gerbils exhibit 
around 50% mortality. Mortality rate increases with decreasing age (95).   
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2.0 Statement of Project and Specific Aims 
Animal models that yield similar disease outcomes as humans are invaluable for defining 
the mechanism of infection for emerging pathogens such as RVFV. Newly developed rodent 
models of neurological and congenital RVF open new doors to elucidating therapeutics for disease 
of the CNS and reproductive system due to their similarity in structure and pathology to what is 
observed in human cases. There is a lack of understanding of how RVFV causes encephalitic and 
congenital disease; namely, how the virus enters these tissues, which cells become infected, and 
whether the pathology is primarily caused by the virus or inflammatory immune cells. Previous 
research into these models characterized viral and immune cell infiltration into whole tissues, 
however, seeing specific infection events at the cellular level is necessary to confirm the infection 
mechanisms of RVF disease trajectory. Based on the data presented above, we hypothesize that 
early and extensive viral entry into the CNS from AERO exposure causes an inflammatory immune 
cascade that results in lethal encephalitic disease, accounting for the difference in mortality from 
that seen in SUBQ models. In the congenital rodent model, we hypothesize that RVFV is able to 
directly infect the maternal-fetal interface of the placenta, which is made up of immunologically-
privileged cell types; the affinity of RVFV to these cell types allows for severe reproductive system 
pathology and miscarriages similar to what is seen in livestock, and, potentially, humans. We will 
use the following specific aims to address unmet needs in visualization of RVFV infection in CNS 
and reproductive tissues:  
 
Aim 1: To develop immunofluorescence staining techniques to characterize the trajectory of 
RVFV infection and corresponding inflammatory immune response in the nasal epithelium 
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and brain during RVF encephalitis in rats. The repercussions of immune cell infiltration into 
the central nervous system (CNS) during RVFV aerosol infection are not extensively studied. Our 
lab observed that the immune response to infection was at least partly responsible for uncontrolled 
inflammation and cytokine storms resulting in tissue pathologies in the rat model of RVF 
encephalitis. In vitro infections show neuronal and microglial cell types to be permissible to 
RVFV. Our working hypothesis is that inhaled Rift Valley fever virus first infects the olfactory 
epithelial neurons and travels across the axons into the olfactory bulb of the brain. Viral infection 
then stimulates an influx of inflammatory immune cells that further damages the neuronal 
population and, ultimately, leads to the death of the animal. Fluorescent RNA in situ hybridization 
(RNA ISH) of viral RNA and immunostaining of immune cell infiltrates will be used to identify 
inflammatory cell infiltrates and resulting pathologies of infected rat brains and snouts compared 
to uninfected controls.  
 
Aim 2: To define the mechanism of RVFV infection in the placenta and reproductive tissues 
of pregnant Sprague-Dawley rats. Our recent work defined the first rodent model of vertical 
transmission of RVFV. Pregnant rats were more likely to succumb to infection than non-pregnant 
rats, and the virus was able to bypass the antiviral protections of the reproductive system and 
directly infect the placenta. Even asymptomatic mothers that survived to give birth produced 
stillborn pups or pups with severe abnormalities.  Little is known about the mechanism of viral 
infection in the placenta and the resulting fetal pathology. Our hypothesis is that RVFV infects 
otherwise protected reproductive structures and stimulates an inflammatory immune response that 
damages the fetus during gestation resulting in growth restriction and fetal death. RNA ISH of 
viral RNA and immunohistochemical (IHC) staining of immune cells will be used to identify 
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inflammatory cell infiltrates and the resulting pathologies of lethally infected and sublethally 
infected rat maternal and fetal tissues compared to that of infected non-pregnant, pregnant 
uninfected, and non-pregnant uninfected controls.  
Characterizing the timeline of RVFV infection and immune cell infiltrates responsible for 
pathogenesis in encephalitic and congenital models of RVF is crucial for elucidating targets for 
antiviral therapies. This work will provide preliminary insight into the cellular targets of RVFV 
and the host immune response and aid in determining the major cause of tissue damage during 
encephalitic and congenital RVFV.  
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3.0 Materials and Methods 
3.1 Biosafety 
All work with ZH501 RVFV was performed in the biosafety level 3+ Regional 
Biocontainment Laboratory (RBL) at the University of Pittsburgh. Personnel wore powered air 
purifying respirators (PAPRs), waterproof apron, and facility designated shoes.  The RBL is a 
shower-out facility that requires a full clothing change into scrubs before entry and a personal 
shower and new scrubs upon exit. Work was conducted in a class III biosafety cabinet (BSC) using 
Vesphene IIse (Steris Corporation, cat. #646101) at a 1:128 working dilution as a disinfectant. All 
tissues or samples removed from BSL-3 were inactivated using methods described below; all 
inactivation methods have been verified and approved by a University of Pittsburgh biosafety 
oversight committee.  
3.2 Virus and Cells 
The ZH501 strain of RVFV used in these experiments was provided by Barry Miller (CDC, 
Fort Collins, Colorado) and Stuart Nichol (CDC, Atlanta, Georgia). Virus was propagated from 
VERO E6 (CRL-1586, American Type Culture Collection) cells in standard culture conditions 
using Dulbecco’s modified Eagle’s medium (DMEM) containing 2% (D2) or 10% (D10) fetal 
bovine serum (FBS), 1% penicillin-streptomycin (pen/strep), and 1% L-glutamine.  
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3.3 Rat Experiments 
All animal work was conducted at animal biosafety level 3+ (ABSL-3+) conditions. 
Experimental plans were reviewed and approved by the University of Pittsburgh IACUC. For the 
encephalitic RVFV model, female Lewis rats (8-10 weeks of age) were infected with RVFV 
ZH501 at 3x104 pfu for aerosol (AERO) exposure and 1x105 pfu for subcutaneous (SUBQ) 
exposure. Two rats were euthanized per day from days 1-7 dpi to collect tissues. Rats meeting 
euthanasia criteria before 7 dpi (end of experiment) were sacrificed. Aerosol infections were 
performed in a class III aerobiology cabinet. 
Sprague-Dawley (SD) (6 to 8 weeks of age) were inoculated in the hind flank with 500uL 
of RVFV ZH501 diluted with DMEM + 2% FBS. Pregnant rats were inoculated on embryonic day 
(E) 14 (by this time the placenta has fully formed) in four different dose groups (7.5 x 101 pfu, 1.8 
x 102 pfu, 1.5 x 103 pfu, and 2.6 x 104 pfu). Dams that met euthanasia criteria were sacrificed, 
otherwise they were sacrificed at 18 dpi along with their surviving offspring. Nonpregnant dams 
were euthanized at 16 dpi unless euthanasia criteria were met beforehand. 
3.4 Tissue Preparation 
3.4.1  Central nervous system sample preparation for immunofluorescent in situ 
hybridization 
Lewis rat tissues were perfused with 500mL of 4% paraformaldehyde (PFA) following 
euthanasia to ensure complete inactivation of tissues in the entire animal then then submerged in 
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fresh 4% PFA and stored at 4°C for fixation for at least 3 hours (brain tissue) or 1 week (whole rat 
head/snout) before removal from BSL-3 conditions. Tissues were cryoprotected using 30% 
sucrose and flash frozen with liquid nitrogen-cooled 2-methylbutane. Frozen samples were 
sectioned at 7m using a microtome supplied by the University of Pittsburgh Center for Biologic 
Imaging.  
3.4.2  Nasal turbinate tissue preparation for immunofluorescence  
Heads (1 per timepoint) from the Lewis rat encephalitic model were submerged in 4% PFA 
after perfusion fixation for 1 week before removal from BSL-3 conditions. Due to nasal turbinate 
bone in the tissues, samples required a decalcification step with pH 7.4, 10% 
ethylenediaminetetraacetic acid (EDTA) with distilled water for three weeks; each week the 
sample was moved to a container of fresh EDTA; EDTA is gentle on tissues, preserves DNA, and 
ideal for use with immunofluorescence (96). After decalcification, the heads were washed with 1x 
PBS and placed in 70% ethanol for transport to the University of Pittsburgh, McGowan Institute 
Histology Core for paraffin embedding and sectioning of the region of the turbinate with the most 
olfactory epithelium surface area (T3 and T4).  
3.4.3  Reproductive tissue sample preparation for chromogen in situ hybridization 
Pregnant SD rat tissues were harvested without perfusion and submerged in 4% PFA for 
24 hours and stored at 4°C. Samples were moved into fresh 4% PFA for removal from the BSL-3 
facility. Tissues were paraffin embedded and sectioned at the University of Pittsburgh McGowan 
Institute Histology Core.  
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3.5 RNA In Situ Hybridization and Immunofluorescence  
3.5.1  Encephalitic model immunofluorescence and in situ hybridization of brain tissues 
The neurological RVFV serial sacrifice experiment contained 16 Lewis rats; two 
uninfected controls, and two rats per day post-infection (1 dpi through 7 dpi). All replicates (two 
rats per day) were stained and imaged along with a primary delete slide that did not receive the 
primary antibody incubation step. The primary delete internal control is used to determine if tissues 
express non-specific fluorescence or if the secondary antibodies bind non-specifically; images of 
this slide are used to set analysis parameters. Slides were stained in slide boxes lined with wet 
paper towels (in order to create a humidity chamber to prevent the samples from drying out) and 
placed in an incubator at 37°C in place of the RNAscope hybridization oven; this method was able 
fit more slides in one experimental run than the hybridization oven, which only holds 20 slides. 
Slides were permeablized for 30 minutes using 0.1% TritonX100 detergent + 1x PBS at room 
temperature (RT, 25°C); permeablizer was placed on the slide in enough volume to cover the 
tissue. TritonX100 is a strong detergent that partially lyses cell membranes which is required for 
viral antigen and probe staining. The protease step in the RNAscope kit was omitted to preserve 
microglia and neuronal antigen, which are degraded by this reagent. Slides were stained in slide 
boxes lined with wet paper towels and placed in an incubator at 37°C in place of the RNAscope 
hybridization oven. Donkey serum (20% in 5% BSA + 1x PBS), specific to the host of the 
secondary antibodies, was used to block non-specific binding of secondaries for 45 minutes at RT. 
Primary antibodies that target microglia (goat anti-IBA-1; Novus, Catalog #NB100-1028; used at 
1:100 with 5% BSA + 1x PBS), neutrophils (rabbit anti-myeloperoxidase; Abcam, catalog 
#ab9535; used at 1:200 with 5% BSA + 1x PBS), and leukocytes (mouse, cy5 pre-conjugated 
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CD45; BD Pharmigen, catalog #565465; used at 1:100 with 5% BSA + 1x PBS), and a dye that 
stains neuronal Nissl bodies (647-conjugated Neurotrace; Invitrogen, catalog #N21843; used at 
1:100 with 5% BSA + 1x PBS),  were incubated for 1 hour at 4°C. Fluorescent secondary 
antibodies that target the primary antibody host species (Donkey anti-goat IgG H&L Alexa Fluor 
488, Abcam, catalog #ab150129; Cy™3 AffiniPure Donkey Anti-Rabbit IgG (H+L), Jackson 
ImmunoResearch, catalog #711-165-152) were incubated for 1 hour at RT in order to tag primary 
antibodies. Hoescht (Bis-benzamide) was incubated for 1 minute to counterstain the nuclei at 450 
nanometers (nm). Samples were mounted using a glycerol and polyvinyl alcohol (PVA) mixture.  
3.5.2  Encephalitic model immunofluorescence of nasal epithelial tissues 
Nasal turbinate slides were deparaffinized using an alcohol dehydration series (100%, 95%, 
and 70%; each step was repeated two times using fresh reagents and a 20-minute incubation time; 
increased incubation time was needed to account for size of tissue section). Slides underwent an 
antigen retrieval process by boiling in pH 6.0, 10mM sodium citrate buffer with 0.05% Tween-20 
for 15 minutes to unmask antigen and probe-binding epitopes. Slides were permeablized for 30 
minutes using 0.1% TritonX100 detergent + 1x PBS at RT; Serum specific (20% in 5% BSA + 1x 
PBS) to the host of the secondary antibodies (donkey) was used to block non-specific binding of 
secondaries for 45 minutes at RT. Primary antibodies that target olfactory epithelial neurons (sheep 
anti-OMP; Thermofisher, catalog #OSS00001W, used at 1:200 with 5% BSA + 1x PBS) and 
RVFV NP antigen (supplied by Dr. Anita McElroy, University of Pittsburgh Center for Vaccine 
Research; used at 1:100 with 5% BSA + 1x PBS) and a dye that stains neuronal Nissl bodies (647-
conjugated Neurotrace; Invitrogen, catalog #N21843; used at 1:100 with 5% BSA + 1x PBS),  
were incubated for 1 hour at 4°C. Fluorescent secondary antibodies that target the primary antibody 
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host species (Donkey anti-Sheep IgG H&L Alexa Fluor 488, Abcam, catalog #ab150177, used at 
1:500 with 5% BSA + 1x PBS; Cy™3 AffiniPure Donkey Anti-Rabbit IgG (H+L), Jackson 
ImmunoResearch, catalog #711-165-152, used at 1:1000 with 5% BSA + 1x PBS) were incubated 
for 1 hour at RT in order to tag primary antibodies. Hoescht (Bis-benzamide) was incubated for 1 
minute to counterstain the nuclei at 450 nanometers (nm). Samples were mounted using a glycerol 
and polyvinyl alcohol (PVA) mixture.  
3.5.3  Congenital model chromogen in situ hybridization 
Placental tissue samples from six pregnant dams were included in the staining and imaging 
set; two uninfected control dams and two lethally infected dams; there were no placentas from 
sublethally infected animals because they are eaten after birth. Liver, uterus, and ovary samples 
from six pregnant animals were included; two uninfected animals, two sublethally infected 
animals, and two lethally infected animals. Slides were deparaffinized using an alcohol 
dehydration series (100%, 95%, and 70%; each step was repeated two times using fresh reagents 
and a 10-minute incubation time). For colorimetric RNA in situ hybridization (ISH), slides 
underwent an antigen retrieval process by boiling in RNAscope target retrieval reagent for 15 
minutes to probe-binding epitopes; slides were placed in a plastic slide holder and submerged in a 
container of the target retrieval reagent which was microwaved on high power until boiling was 
achieved then boiling was maintained at a lower power. Slides were stained in slide boxes lined 
with wet paper towels (in order to create a humidity chamber to prevent the samples from drying 
out) and placed in an incubator at 37°C in place of the RNAscope hybridization oven; this method 
was able fit more slides in one experimental run than the hybridization oven, which only holds 20 
slides. A primary delete slide, for each tissue type, was incubated with an RNA probe, dapB (a 
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gene from the soil bacterium, Bacillus subtilis, strain, SMY) that is not found in rat tissues, rather 
than the RVFV probe; this internal control helps determine if tissues have experienced RNA 
degradation that would result in non-specific staining. The RNAscope kit instructions state that 
results are optimal for tissues less than 3 months of age. The RNAscope kit was, otherwise, used 
according to manufacturer’s instructions; RVFV probe incubation for two hours at 37°C, 
amplifying steps 1-4 for 15-30 minutes at 37°C, and amplifying steps 5-6 for 15 and 30 minutes, 
respectively, at RT. Enough reagent in each step was pipetted onto the slide to cover the entire 
tissue. After the staining procedure, slides were dehydrated by air-drying overnight at RT then 
incubating in xylenes (ethanol was avoided due to RNAscope chromogen, Fast Red, being 
sensitive and, potentially degraded by alcohols) for 1 minute before mounting with a toluene-based 
solution, Permount (Fisher Chemical, SP15-100) for long term chromogen staining storage. 
3.6 Microscopy and Image Analysis 
Immunofluorescent RNA ISH slides were imaged using the Nikon A1 confocal microscope 
provided by the University of Pittsburgh, Center for Biologic Imaging. Images were contrasted 
using Adobe Photoshop and denoised and analyzed using Nikon Elements. Images were analyzed 
for number of specific cell types using Nikon Elements general analysis software. Colorimetric 
RNA ISH slides were imaged using the Tissue Gnostics pathology microscope provided by the 
Center for Biologic Imaging. Images were analyzed for total area (m2) of infected tissue. 
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4.0 Results 
4.1  Aim 1: To Characterize the Trajectory of RVFV Infection and Corresponding 
Inflammatory Immune Response in the Nasal Epithelium and Brain During RVF 
Encephalitis in Lewis Rats. 
Rift Valley fever virus (RVFV) is found in the brains of infected rats 1 dpi after 
subcutaneous (SUBQ) and aerosol (AERO) exposure routes (85, 88); however, aerosol infection 
carries a higher risk of mortality. The mechanisms behind different disease outcomes due to 
exposure route is not well understood and this information is crucial for the development of 
vaccines and therapeutics. Viral antigen and RNA detection quantification methods such as plaque 
assay, q-RT-PCR, and flow cytometry require homogenization of entire tissues and, while they 
provide invaluable quantitative data, they lack the ability to show specific events in the trajectory 
of the virus from the point of exposure. Immunostaining and RNA in situ hybridization (ISH) 
techniques developed in this study highlight RVFV as it travels from the nasal epithelium into the 
CNS. These methods can be used to elucidate the precise route in which the virus travels to the 
brain after aerosol exposure. Use of both anti-RVFV NP antibodies and vRNA probes allow for 
tracking of NP antigen and vRNA, the host cells that are being infected, and the pathway the virus 
takes from beginning to end-stage disease. We sought to develop a reproducible viral staining 
method in Lewis rat tissues in order to visualize RVFV infection of the central nervous system 
(CNS). 
Immunofluorescence (IF) staining of RVFV has been achieved in cell culture (88, 97) but 
staining in tissues yields inconsistent results. Antibodies have been approved for other mediums 
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such as western blots, ELISAs, and flow cytometry, but many have yet to yield reproducible data 
for IF and immunohistochemistry (IHC).  Optimization of previously developed staining protocols 
(provided by the University of Pittsburgh Center for Biologic Imaging; adapted from Coons et al. 
(1941) (98)) and the addition of new steps were required to successfully target RVFV in fixed, 
frozen Lewis rat CNS tissues. Fixation for complete inactivation of RVFV is required for samples 
to be removed from BSL-3 conditions; this process requires the rats to be perfused with 4% PFA 
after euthanasia and for brain tissues to be submerged in fresh 4% PFA for 3 hours before removal. 
This experiment consisted of fourteen rats (12 infected with RVFV and 2 uninfected controls). 
Two rats per day (from 1 to 7 dpi) were euthanized. Neuronal death and encephalitis are the main 
characteristics of neurological RVF, therefore, a staining panel including a neuronal Nissl body 
marker (Neurotrace), microglial cell marker (IBA-1), and RVFV viral RNA (vRNA) NP probe 
was carried out on olfactory bulb (OB) and cortex tissues (Fig. 1 and 2) (88). Extracellular vRNA 
was detected in the glomerular layer (GL) of the OB at 1 dpi and persisted until 3 dpi when the 
first infected neuron (highlighted by magenta arrow in Fig. 1B) was seen within the GL (yellow 
masked cells signifying the colocalization of red pseudo-colored vRNA and green neuronal dye). 
At 4 dpi through end-stage infection, both extracellular and neuronal vRNA staining significantly 
increased (Fig. 3A). Many neurons lining the mitral cell layer (MCL) colocalized with vRNA by 
5 dpi, suggesting that the virus traveled posteriorly from the GL. Virus was found throughout the 
entirety of the OB and the by 6-7 dpi; nearly 25% of neurons were infected (Fig. 3A). At this time, 
signal colocalization of vRNA (red), neuronal Nissl bodies (green), and IBA-1 (white) was 
observed (highlighted by cyan arrow in Fig. 1B) and suggested that activated microglia 
phagocytosed necrotic neuronal debris. Total microglia (defined at IBA+ cells) increased by more 
than double the total cell composition of the uninfected sample at 2 dpi and remained elevated for 
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the duration of infection. Microglia at 2 dpi exhibited a ramified structure like that of quiescent 
microglia but took on a large, amoeboid morphology at 3 dpi until the end of infection (7 dpi); 
which suggested microglial activation in response to pathogen invasion. These data aligned and 
largely supported the flow cytometry data in Albe et al. (2019) (88).  
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Figure 1: Extracellular RVFV vRNA is seen in the olfactory bulb as early as 1 dpi and neuronal infection 
occurs at 3 dpi. 
Aerosol-infected Lewis rat OBs show evidence of increased viral burden (vRNA) within the glomerular layer from 1 
dpi to 7 dpi. RVFV RNA was detected by in situ hybridization immunofluorescence (ISH-IF) (red). Samples were co-
stained with an antibody for microglia (IBA-1; white), a Nissl body dye (Neurotrace; green), and a nuclear counterstain 
(DAPI; blue). (A) 40x micrograph of uninfected control labeled: GL; glomerular layer, EPL; external plexiform layer, 
MCL; mitral cell layer, GCL; granule cell layer. 2x2 field large images at 40x magnification were stitched using Nikon 
Elements software (scale bar = 100um). Yellow arrows indicate areas with viral RNA in the glomerular layer that is 
magnified in (B). (B) Max intensity projection images of the glomerular layer taken at 60x (scale bar = 50um). Yellow 
arrows indicate infected neurons. (88) 
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Timing of cellular events in the cortex was similar to that of the OB. Extracellular virus 
was seen at 1 dpi, but infected neurons were not seen until 3 dpi. Massive neuronal infection and 
death with phagocytosis of infected neuronal debris by microglia was seen from 5 dpi to 7 dpi. 
The microglial population spiked at 2 dpi and, over the time course of infection, changed from 
quiescent, branched structures to activated, macrophage-like morphology. By 7 dpi, the population 
of infected cells and infected neurons significantly increased to 20% and 30%, respectively (Fig. 
3B). 
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Figure 2: Extracellular RVFV vRNA is seen in the cortex as early as 1 dpi and neuronal infection occurs at 3 
dpi. 
Aerosol-infected Lewis rat prefrontal cortexes show evidence of increased RVFV vRNA over the course of infection 
(1 dpi to 7 dpi). RVFV RNA was detected by ISH-IF (red). Samples were co-stained with an antibody for microglia 
(IBA-1; white), a Nissl body dye (Neurotrace; green), and a nuclear counterstain (DAPI; blue). Yellow arrows 
highlight infected neurons. Single field 60x magnification images taken with a Nikon A1 confocal microscope (scale 
bar = 50um).(88) 
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Flow data in Albe et al. (2019) showed neutrophils and macrophages (peripheral or 
activated microglia; stained for CD45, a pan leukocyte marker) infiltrating the CNS upon RVFV 
infection. It is hypothesized that these cells contributed to inflammation and neuronal death. To 
characterize these cell types, another staining panel (Fig. 4 and 5) was performed using primary 
antibodies for CD45, myeloperoxidase (MPO) (an antimicrobial enzyme secreted by neutrophils), 
and IBA-1. The CD45 antibody for IF only detects CD45med to CD45high, which was found in 
peripheral macrophages and activated microglia; the flow cytometry antibody can detect CD45low 
expressed by quiescent microglia. However, even with this difference in antibody affinities, the 
data between the two mediums supported each other. It should be noted that by this IF panel, 
quiescent vs. activated microglia were mainly distinguished by having branched or amoeboid 
morphologies whereas peripheral macrophages only exhibited amoeboid morphology.  
Leukocytes (green) were seen infiltrating the OB from the BBB to the GL by 1 dpi. These 
numbers remained low until 5 dpi when a shift in cell composition occurred; neutrophils were seen 
infiltrating while the number of quiescent microglia decreased and began shifting to the amoeboid 
shape. At 6 dpi, there was massive breakdown of the BBB and significant, systemic influx of 
leukocytes (peripheral or activated microglia; CD45+ and IBA+ cells (Fig. 6A-D)) and neutrophils; 
cells with colocalization of multiple markers also significantly increased on days 6 and 7 dpi (Fig. 
6B and 6D).  At 7 dpi total cell numbers decreased (Fig. 6B) and localized mainly to the GL. The 
cortex followed a similar trend aside from showing neutrophil influx at 1 dpi at low numbers which 
persisted until the BBB breakdown event seen in 5 dpi (Fig. 5). Interestingly, there were branched 
microglia in the cortex until 7 dpi whereas the microglia population in the olfactory bulb were 
entirely amoeboid by 5 dpi.  
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Taken together, these results corroborated data from Albe et al. (2019) showing infiltrating 
neutrophils and macrophages as a hallmark of encephalitic RVF in Lewis rats. These leukocytes 
were seen entering the CNS tissues between 2-4 dpi (after initial virus entry at 1 dpi) by complete 
blood count (CBC) and flow cytometry, then, following the major BBB breakdown event around 
5 dpi, infiltrated en masse shortly before mortality. Aerosol exposure consists of inhalation of 
RVFV droplets through the nose; olfactory epithelial neurons (OEN) within the nasal epithelium 
connect directly to the OB through the cribriform plate. Due to RVFV initially appearing in the 
GL of the OB at 1dpi, it seems likely that access to this OENs after aerosol exposure could be the 
mechanism of severe infection. If RVFV is able to either infect or travel along the OENs between 
exposure and 1 dpi, then that mechanism could account for the differences in disease outcome 
between the AERO and SUBQ models. To determine this, nasal epithelium was stained for RVFV-
NP antigen, and OEN marker (OMP), and Neurotrace (Fig. 7). On 1 dpi, RVFV antigen was seen 
along the OEN epithelium and within the lamina propria layer beneath the epithelium. 
Colocalization of RVFV, OMP, and DAPI (yellow cells) on 1 dpi represented infected nasal 
epithelial neurons. RVFV signal was at its highest on 3-4 dpi right before the clinical window of 
disease when neuronal infection began in the OB and cortex. On 5-7 dpi RVFV antigen signal 
decreased (Fig. 7). 
In summary of Aim 1, I have developed a reproducible optimized staining panel to detect 
both RVFV RNA and NP antigen to identify neuronal infection and inflammatory cell infiltration 
in Lewis rat nasal epithelium and brain tissues that can be utilized to determine location of these 
infection events alongside quantitative cell sorting methods used on tissue homogenates. 
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Figure 3: Aerosolized RVFV infection results in a significant increase in infected cells during the clinical 
window. 
Mean percentage of infected cell types in the (A) olfactory bulb and (B) cortex over the course of AERO RVFV 
infection. Two-way ANOVA with multiple comparisons was used to determine statistical significance between daily 
timepoints and the uninfected control. Infected cell composition was significant in the 5, 6, and 7 dpi samples 
compared to the uninfected control; infected neuron composition was significant in the 7 dpi samples compared to the 
infected control (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).  
 
B 
A 
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Figure 4: RVFV AERO infection results in leukocyte infiltration into the OB as early as 1 dpi. 
Aerosol-infected Lewis rat olfactory bulbs show evidence of increased cell infiltration from 1 dpi to 7 dpi. Samples 
were stained with primary antibodies to detect neutrophils (MPO; red), a pan-leukocyte marker (CD45; green), and 
microglia (IBA-1; white) along with a nuclear counterstain (DAPI; blue). (A) 2x2 field images were taken with at 40x 
magnification (scale bar = 100um). Yellow arrows indicate areas of leukocyte infiltration magnified in (B). (B Max 
intensity projection images of the olfactory bulb taken at 60x (scale bar = 50um). Cyan arrows indicate neutrophil 
infiltration. (88) 
 37 
 
Figure 5: RVFV AERO infection results in leukocyte infiltration into the cortex as early as 1 dpi. 
RVFV-infected Lewis rat cortexes show evidence of increased leukocyte cell infiltration from 1 dpi to 7 dpi. 
Samples were stained with primary antibodies to detect neutrophils (MPO; red), general leukocytes (CD45; green), 
and microglia (IBA-1; white) along with nuclear counterstain (DAPI; blue). Max intensity projection images of the 
cortex blood brain barrier taken at 60x. Yellow arrows highlight leukocyte infiltration and cyan arrowheads 
highlight neutrophil infiltration (Scale bar = 50um). (88) 
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Figure 6: The clinical window of RVF is marked by significant increases in inflammatory immune cells. 
Mean percentage of inflammatory cell types in the (A and B) olfactory bulb and (C and D) cortex over the course of 
AERO RVFV infection. Two-way ANOVA with multiple comparisons was used to determine statistical significance 
between daily timepoints and the uninfected control. Leukocyte compositions in the olfactory bulb (OB) and cortex 
were significant in the 6 dpi samples compared to the uninfected control; CD45+ microglia compositions in the OB 
and cortex were significant at 6-7 dpi; MPO+ microglial cells, CD45+ neutrophils, and MPO+ microglia were 
significant in the cortex at 6-7 dpi compared to the control (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 
0.0001).  
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Figure 7: RVFV antigen and infected olfactory epithelial neurons can be seen in the olfactory epithelium and 
lamina propria as early as 1 dpi.  
Images (40x) of aerosol-infected Lewis rat nasal epithelium show evidence of increased RVFV antigen beginning at 
1 dpi. RVFV was detected by an anti-NP antibody (red). Samples were co-stained with an antibody for neurons 
(Neurotrace; white), olfactory epithelial neurons (OMP; green), and a nuclear counterstain (DAPI; blue).  
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4.2   Aim 2: Define the Mechanism of RVFV Infection and Inflammatory Immune 
Response in the Placenta of Late-Gestation Pregnant Sprague-Dawley Rats. 
Vertical transmission of RVFV has been reported in a handful of human case studies that 
resulted in neonatal viremia (42), liver pathology (41), and death (42). The ability of RVFV to 
cause abortion storms in livestock, taken with human cases, suggest that the virus is able to pass 
to the fetus from an infected mother. The congenital side effects of ZIKV were generally unknown 
before the outbreak in the Americas in 2015. Of the 28,000 confirmed cases, about 1,000 (4%) 
were pregnant women (99). The medical consequences of ZIKV illuminated the need for 
therapeutics for sensitive populations, such as pregnant individuals. In vivo experiments by Platt 
et al. (2018) showed that the encephalitic arboviruses, CHIKV, Powassan virus (POWV), WNV, 
and Mayaro virus (MAYV) were all able to infect mouse placentas and that WNV and POWV 
induced fetal demise. In McMillen et al. (2018), our lab was concerned about the ability of RVFV 
to cross the maternal-fetal interface; therefore, we inoculated pregnant (gestational age E14) SD 
rats with pathogenic RVFV (ZH501) and examined the maternal and fetal tissues for viral 
dissemination, cellular targets of infection, and resulting pathology (44).  
Typical RVFV IHC techniques showed varying results in rat tissues; the most successful 
RVFV antibody (IBT Bio Services, Cat# 04-0001) has recently been discontinued. Archived 
pregnant rat tissues were embedded in paraffin blocks to allow for the preservation of structural 
integrity and convenient long-term storage. Paraffin wax must be removed in order to dye or stain 
tissues and requires a xylenes and ethanol dehydration series which can further damage viral and 
cellular epitopes of interest or cause nonspecific binding of chromogens and fluorophores. Sample 
preparation and staining required optimization in order to achieve a reproducible method viral 
detection. The choice to adopt the ACD Bio RNAscope 2.5 HD Red Detection kit assay resulted 
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from continued failure of current primary antibody options. The probe used in this kit targets an 
RNA sequence within the nucleocapsid protein (NP) which allows for observation the precise 
location of NP, the most abundant viral component.  
Rats were age-matched and time-mated at 6-8 weeks of age. Presence of a copulation plug 
was used to verify pregnancy and determine gestational time; early (embryonic day 5 (E5)) or late 
(E14). Rats were infected via SUBQ hindlimb injection at E14 (when the placenta is fully formed). 
If rats met euthanasia criteria they were sacrificed, otherwise, they were left to give birth on E22 
and were left undisturbed for 5 days postdelivery; during this period, rats often eat placentas so 
samples from surviving rats were not able to be obtained. Samples from dams that were euthanized 
previous to E22 (8-9 dpi) were considered lethal samples and dams that survived to give birth were 
considered sublethal samples. Placental samples were divided into late-gestation and early-
gestation groups based on death occurring before or after E19-E20 (5-6 dpi). Exploring differences 
in fetal development and viral titer between the gestational groups helps to determine the role of 
infection in fetal demise.   
RVFV vRNA was detected in the maternal-fetal interface made up of the maternal decidua 
and fetal basal zone (seen in Fig. 8A, E, F, and G) in a dam that died at the end of the early-
gestation range, on 6 dpi (E20) and in a dam that died late in gestation, while giving birth, at 9 dpi 
(E23). RVFV is able to infect the same structures between these gestational groups, however,  
maternal and fetal demise typically occurs in late gestation (44). The additional viral infiltration 
and resulting massive tissue death within the late gestation placenta may account for the skew 
towards later mortality. The maternal and fetal interface layers are known to exhibit antiviral and 
antibacterial immune responses, such as type III IFN production, which renders these tissues 
resistant to infection by other pathogens such as ZIKV (100). In the case of RVFV, direct infection 
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of this layer may account for high viral loads and lethal fetal outcomes. Trophoblast giant cells 
(TGC) in the basal zone interact with the maternal decidua to facilitate fetal implantation and 
become “invasive” once the layers have fused completely (91). It can be seen in Fig. 8G that these 
cells are also infected by RVFV which suggests another mechanism of direct infection at the 
maternal-fetal interface. The amnion (Fig. 8E), connective tissue that encapsulates the fetus and 
amniotic fluid (92), was also the target of infection as well as trophoblast cells within the fetal 
labyrinth zone (Fig. 8F). 
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Figure 8: RVFV targets the basal zone, decidua, and amnion of pregnant rat placentas.  
Colorimetric RNA ISH staining of RVFV RNA (red) with hematoxylin counterstain (blue). (A) 20x image of 
infected rat placenta that died 3 dpi/ E20 labeled for relevant maternal and fetal layers (Scale = 250um). (B-D) 
Uninfected control, (E-G) dam that died 3 dpi, (H-J) dam that died while birthing on 9 dpi. Black arrowheads 
highlight areas targeted by virus; (B, E, H) amnion, (C, F, I) decidua and trophoblast giant cells of the basal zone, 
and (D, G, J) trophoblasts within the labyrinth zone (Scale = 25um). 
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RVFV is considered a promiscuous virus due to its vast tissue tropism. It was originally 
understood to be a hepatotropic virus, however, depending on the route and model of infection 
viral loads have been found to be just as high in other organs such as the brain (88) and placenta 
(44). In congenital RVFV, the uterus and ovaries are targeted by the virus in both lethal and 
sublethal groups, exhibiting near 105 pfu/ml (compared to 106 pfu/mL seen in the liver and 
placenta). Using the liver from lethally infected dams as a positive control tissue for comparison, 
it can be appreciated that the ovary of the lethally infected pregnant dam in Fig. 9 shows 
widespread infection. The uterus, to a lesser extent, showed virus throughout, slightly homing to 
the vasculature edges.  Histopathological assessment in McMillen et al. (2018) marked necrotic 
legions and acute inflammation in the uteruses of both dams lethally and sublethally infected. The 
ovaries showed no signs of pathology, yet viral RNA was widespread throughout.  
McMillen et al. (2018) observed the liver having the second highest amount of viral RNA 
by qRT-PCR and plaque assay, however, colorimetric ISH analysis showed the liver to have the 
second lowest amount of viral staining area among the tissues (Fig. 10). Sensitivities in vRNA 
detection among the techniques may account for these differences. Additional samples of each 
tissue type must be added to the sample set to increase the reliability of image analysis.  
In summary of Aim 2, I have developed a reproducible and optimized staining panel to 
detect vRNA in FFPE rat tissues in order to determine the cellular targets of RVFV in the placenta 
and reproductive organs of pregnant rodent model. This model of infection has not yet been studied 
before its development in McMillen et al. (2018) and will elucidate the effects of ongoing RVFV 
infection in pregnant rodents as well as animals with similar placental structures.  
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Figure 9: RVFV systemically infects liver, ovaries, and uterus of lethally infected pregnant dam. 
Images (20x) of colorimetric RNA ISH staining of RVFV RNA (red) with hematoxylin counterstain (blue) within 
the indicated tissues of uninfected, lethally infected, and sublethally infected dams. (Scale bar = 100um).  
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Figure 10: The reproductive organs of infected dams exhibit more vRNA staining than the liver during 
congenital RVFV infection.  
Colorimetric ISH images from uninfected, sublethally infected, and lethally infected pregnant dam tissues were 
measured for vRNA area (m2) and normalized against total tissue area (m2). Placentas from sublethally infected 
dams were not available for analysis; only uninfected and lethally infected are represented.  
N
D
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5.0 Discussion 
Since its official discovery in 1931 (12), Rift Valley fever virus (RVFV) has caused known 
outbreaks in continental Africa (12, 13, 15-19, 101), the Saudi Peninsula (8), Madagascar (20), 
and Yemen (8). Massive livestock mortality events highlight the economic burden of RVFV 
epidemics. While mosquitos facilitate subcutaneous (SUBQ) disease spread between livestock, 
wild ruminants, and humans, exposure to aerosolized (AERO) RVFV from inhalation of infected 
tissues and feces may be associated with a higher risk of severe disease outcomes such as 
meningoencephalitis (85, 88) or ocular disease (8, 39, 40). Human cases of respiratory exposure 
to RVFV have occurred in laboratory settings but have not been reported from outbreaks during 
endemic regions; there is not enough epidemiological data to link exposure with severe disease 
outcomes. Aerosol infection studies in rats (56, 82, 85-88), mice (77-79), and non-human primates 
(NHPs) (93, 94) have shown higher mortality rates than other exposure routes such as SUBQ (88) 
and intraperitoneal (IP) (102). RVFV has been aerosolized by the United States (US) and Russian 
governments and remains highly stable and able to be transmitted via inhalation (73) and can be 
used as a potential bioterrorism agent (54, 103).  
A large case study of 683 individuals with laboratory confirmed (IgM+) Rift Valley fever 
(RVF) during the Saudi outbreak characterized the most common symptoms as fever (93%), 
central nervous system (CNS) manifestations (17%), hemorrhagic manifestations (7%), and vision 
loss (2%) (8). Of the 81 individuals with CNS symptoms, confusion, lethargy, disorientation, 
vertigo, coma, tremors, and amnesia all made up more than 1% of cases. Individuals with CNS 
symptoms were also 14.2 times more likely to succumb to disease than those without a 
neurological component (8); this is the highest odds ratio behind bleeding manifestations resulting 
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in a 20 times higher likelihood of death. One case of an RVFV-seropositive individual in South 
Africa in 1975 dying of meningo-encephalitis showed pathological signs of perivascular cuffing 
and round-cell infiltration (104) which are also seen in the brains of NHP models exposed to 
aerosolized RVF (93). The development of NHP and rodent models of encephalitic RVF are 
crucial research tools for illuminating the mechanism of infection separating self-limiting febrile 
disease from severe CNS and ocular outcomes.  
Albe et al. (2019) compared the mortality and clinical manifestations of Lewis rat models 
exposed to AERO and SUBQ RVFV; AERO rats developed neurological symptoms (decreased 
activity, hunched posture, porphyrin staining of the eyes and nose, erratic behavior, circling, or 
rolling (82)) by 5 dpi and succumbed to disease between 6-7 dpi whereas SUBQ rats survived and 
never developed clinical symptoms. The most striking finding between the two exposure models 
was that viral RNA was found in the brains of both models at 1 dpi (88). The ability to fight off 
CNS infection in the SUBQ model vs. the AERO model is not understood and is a critical piece 
of the puzzle for therapeutic options targeting neurological RVF. The data generated in Albe et al. 
(2019) via q-rt-PCR, complete blood count (CBC), and flow cytometry quantified viral titer and 
cell composition from whole tissue homogenates, whereas AIM 1 in this paper sought to determine 
this information from 7m thick tissue sections in order to highlight specific areas of viral and 
immune cell infiltration to better hone in on the mechanism of infection.  
IF microscopy results corroborated the event of major viral RNA increase in the olfactory 
bulb happening between 4-5 dpi, with the percentage of infected cells increasing up to 40% in the 
olfactory bulb (OB) and 30% in the cortex There is a small increase of infected cells, infected 
microglia and infected neurons in the OB on 1 dpi; this trend occurs on 2 dpi in the cortex. The 
viral staining panel also allowed visualization of viral descent into the OB of rats, originating in 
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the GL as early as 1 dpi and infecting neurons by 3 dpi. The glomerular layer (GL) contains the 
axons of olfactory epithelial neurons (OEN) which are the point of attachment between the CNS 
component of the snout and the OB; the initial presence of RVFV in this region suggests the ability 
of the virus to either directly infect OENs and enter the brain (as seen with herpes simplex type-1 
virus (105)) or travel through neuron unsheathing cell channels (as seen in LACV infection (106)) 
rather than other mechanisms such as hematogenous entry via interruption of the blood brain 
barrier (BBB) (as seen with Ebstein-Barr virus (107)) “trojan horse” entry into the BBB via 
infection of monocytes (as seen in SIV infection (108)), or travel through neuromuscular junctions 
(as seen with poliovirus (109, 110)). Viral RNA (vRNA) is not seen near the endothelial outer 
layer of the BBB in the immunofluorescence (IF) micrographs during early infection which should, 
otherwise, be observed if it were the initial infection route. A staining panel with CD45 and RVFV 
would be necessary to judge whether the trojan horse method of entry is occurring, although, there 
are not infected cells near the BBB perimeter in either the OB or cortex.  
RVFV antigen is seen within the OEN and lamina propria layer of nasal epithelium at 1 
dpi which supports the idea that AERO exposure may allow for extensive viral entry into the OB 
by these mechanisms which can overwhelm the immune response; virus entering the brain at 1 dpi 
in the SUBQ model may not yield a high enough amount of infectious virus, which could account 
for the differences in disease severity. Additional research into the role of OENs during RVFV 
AERO infection will be necessary to determine the exact mechanism of CNS entry and to target 
for therapeutics for neurological disease. Entire RVFV-infected rat heads with intact OBs would 
be necessary for viral and axonal staining to observe whether the virus is infecting OENs or 
traveling through ensheathing channels. Munster V.J. et al. (2012) shows immunohistochemistry 
(IHC) micrographs of Nipah virus antigen colocalizing with OEN axons crossing the cribriform 
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plate in hamster nasal epithelium (111); developing similar staining panels would help determine 
RVFV’s entry mechanism. 
Confirmed cases of human vertical transmission of RVFV are limited to two case studies 
resulting in two infected pregnant women giving birth to both an infant with jaundice, an enlarged 
liver, and an enlarged spleen (41), and an IgM+ infant that died a week after delivery (42), 
respectively,  and a cross-sectional study that found that 54% of pregnant women (15 of 28) with 
an ongoing RVFV infection experienced a late-term miscarriage (odds ratio 7·4, 95% CI 2·7–20·1; 
p<0·0001) (43). While epidemiological data on this occurrence in humans is limited, the 
prevalence of abortion storms among livestock suggests that the virus is able to target reproductive 
tissues and pass to fetuses. McMillen et al. (2018) developed a reproducible rodent model of 
congenital RVF to address vertical transmission in a model that more similarly represents the 
placental structure of humans.  
Human and rat placentas are hemochorial, meaning the maternal blood is in direct contact 
with the chorion, the outermost membrane that encloses the embryo (92) and forms a maternal-
fetal interface. They are also both discoid-shaped, meaning there is a single placenta formed that 
has a discus structure (112). These similarities allow for rats to be used as models of placental and 
reproductive toxicology that can be loosely extrapolated to humans, however, there are key 
differences in the structures that need to be noted. The maternal-fetal interface of the rat is made 
up of three layers (trichorial) of syncytiotrophoblast cells, whereas the human placenta only has 
one layer (monochorial; this begins as two separate that fuse in the first trimester (113)) made up 
of syncytiotrophoblasts and cytotrophoblasts (112). Within the interface, on the fetal side, the 
labyrinth zone of rats is functionally similar to the villous layer of humans; humans have more 
extreme extravillous trophoblast invasion of the interface than rats (113). The middle layer, the 
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basal zone of rats is similarly to the basal plate of humans. The maternal-most layer, the decidua 
and metrial gland are similar to the decidua of humans (112); the metrial gland contains 
endometrial stromal cells, arteries, fibroblasts, and uterine natural killer cells (uNK). The yolk sac 
of the rat placenta eventually grows to cover the amnion and embryo and contributes nutrients, 
whereas the human yolk stalk becomes vestigial after the first trimester (112). Developmental 
issues of the yolk sac in the rats can lead to fetal malformations (113) which adds other concerns 
for infection mechanism differences between the models. The layer separating the yolk sac from 
the embryo in the fetal membrane, the amnion, is found in both human and rodents; the absence 
of the yolk sac in humans may allow more virus to pass to the amnion which has shown to be 
permissive to RVFV infection. These differences, taken together, highlight the importance of 
recognizing structural dissimilarities and the roles they may play during infection and 
transmission.  
RVFV vRNA is observed within each of the three layers of the rat placenta; the decidua 
and metrial gland, basal zone, and labyrinth zone, yolk sac, and amnion. Platt et al. (2018) 
performed footpad injection of flaviviruses (Powassan virus (POWV) and West Nile Virus (WNV) 
and alphaviruses (Chikungunya virus (CHIKV) and Mayaro virus (MAYV)) on pregnant, wildtype 
(WT) mice and found that all viruses were able to infect and replicate in the placenta, however, 
only POWV and WNV caused fetal demise. Further investigation showed WNV and POWV 
vRNA in each of the three layers by RNA ISH and qtPCR, however, CHIKV and MAYV did not 
replicate efficiently in the villi and decidual layers (100). The alphavirus infectivity is similar to 
that seen in ZIKV infection of WT mice (114). The inability of other viruses capable of congenital 
infection to successfully infect the maternal decidua and fetal labyrinth zones of rodent highlights 
the unique tropism of RVFV. Syncytiotrophoblast cells within the labyrinth zone and fetal-
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maternal interface are typically resistant to viral infections due to production of type III interferons 
(114), such as interferon-γ (IFNγ), which can induce T-cell activation and differentiation and MHC 
class II expression (78). However, the NSs of bunyaviruses acts as an interferon antagonist, 
suggesting an ability to avoid the immune protections of certain placental layers. 
Human second-trimester placental explant experiments support the ability of RVFV (44) , 
POWV, WNV, and ZIKV (100) to infect similar structures (the decidua and villi) whereas CHIKV 
cannot replicate efficiently in the decidua or villi. Despite differences in rodent and human 
placental structure, RVFV, and potentially, other bunyaviruses, have the ability to circumvent 
antiviral immune responses in rodent and human placentas. This must be further investigated using 
cell-specific markers for IHC/IF to determine specific targets within these layers.  
McMillen et al (2018) observed viral replication in the ovaries and uterus of lethal and 
sublethal pregnant dams. Severe pathology including liquefactive necrosis of the uterus was 
observed (44), which is unusual considering the pregnant uterus is thought to be immune-
privileged and can downregulate immune responses to avoid tissue damage in response to neonatal 
antigen (115). This suggests that either RVFV alone has the ability to cause severe uterine 
pathology or that maternal immune cells such as uNK cells become active in response to infection. 
Further immune cell-specific and inflammatory cytokine staining needs to be carried out to 
illuminate the mechanism of tissue damage during congenital RVF.  
Rodent models of neurological and congenital RVF allow for observation into the unique 
tropisms of RVFV. Structural similarities between the CNS and reproductive systems of rodents 
and humans illuminate the potential of RVFV infection to cause multiple, severe disease outcomes 
in its endemic countries as well as naive populations in the event of its spread to new countries. 
The aims in this thesis are a preliminary observation into the poorly understudied disease 
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manifestations of RVF and serve to open the door for mechanistic studies to uncover new 
mitigation strategies and potential therapeutics. 
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